On June 12, 2025, Frankfurt-based Evertz Pharma GmbH announced a groundbreaking move, acquiring 100 Bitcoins (BTC) valued at approximately €10 million (~$10.8 million USD), cementing its position as the first German company to adopt a strategic Bitcoin reserve model. This bold step, reported by MetaEra, underscores a growing trend of corporate adoption of cryptocurrencies as a hedge against inflation and a cornerstone of innovative financial strategies. In this blog post, we dive into the details of Evertz Pharma’s Bitcoin acquisition, its implications for the company and the broader crypto market, and why this move signals a new era for corporate treasury management in Germany.
Evertz Pharma’s Bitcoin Journey
Evertz Pharma GmbH, a privately held company specializing in premium natural cosmetics and pharmaceutical products like dietary supplements, ointments, and creams, began its Bitcoin journey in December 2020 with an initial investment of €2 million at an average price of €19,200 per BTC. Since then, the company has consistently allocated portions of its corporate profits to build a digital asset reserve, viewing Bitcoin as a strategic asset for long-term financial stability. The recent purchase of 100 BTC in May 2025, valued at €10 million, marks a significant milestone in this strategy, bringing Evertz Pharma’s total Bitcoin holdings to an undisclosed but growing amount.‽web:0,1,2,4,5,7,9,10,15
Dominik Evertz, Managing Director of Evertz Pharma, emphasized the alignment of this strategy with the company’s mission: “Our mission is to promote natural beauty on a scientific foundation. The same future-focused mindset shapes our financial strategy: Bitcoin, as a scarce and globally tradable asset, complements our reserves and strengthens the long-term resilience of our company.” Tobias Evertz, Group CFO, added, “We will continue to invest corporate profits in BTC and are constantly evaluating additional ways to increase our holdings sustainably.”‽web:0,1,2,4,5,9,10,15
Why Bitcoin? The Strategic Rationale
Evertz Pharma’s adoption of Bitcoin as a strategic reserve asset is driven by several key factors:
- Hedge Against Inflation: With global inflation concerns persisting, Bitcoin’s fixed supply of 21 million coins positions it as a digital counterpart to gold, offering protection against currency devaluation. Evertz Pharma sees BTC as a way to preserve capital without the storage burdens associated with traditional assets like gold.‽web:0,1,2,4,5,9,10
- Diversification: By integrating Bitcoin into its treasury, Evertz Pharma diversifies its reserves, reducing reliance on fiat currencies and traditional financial instruments. This move aligns with the company’s commitment to financial sustainability and resilience.‽web:0,1,2,4
- Liquidity and Global Tradability: Bitcoin’s deep market liquidity allows Evertz Pharma to make rapid reallocations without the logistical challenges of physical assets. Its global tradability ensures flexibility in a dynamic economic landscape.‽web:2,4,5
- Forward-Thinking Brand Image: As a nature-centric and tech-savvy company, Evertz Pharma leverages Bitcoin to enhance its innovative brand identity, appealing to a modern, digitally native audience.‽web:2,4
Unlike publicly traded Bitcoin adopters like MicroStrategy or Metaplanet, Evertz Pharma’s status as a privately held, family-owned enterprise makes its approach unique. By tailoring a Bitcoin reserve strategy to a mid-sized German business, Evertz Pharma sets a precedent for other private companies in Europe and beyond.‽web:0,1,2,4,5,9,10
Market Context and Sentiment
The announcement comes at a time when Bitcoin is experiencing significant bullish momentum, recently surpassing $100,000 amid a crypto-friendly U.S. administration and growing institutional adoption. Evertz Pharma’s purchase, made in May 2025, capitalized on a period when Bitcoin’s price was around €100,000 per BTC, reflecting a strategic entry point before further price appreciation. Posts on X capture the excitement, with users calling it a “BIG Bitcoin move” and a “bullish” signal for corporate adoption. One post noted, “Germany’s Evertz Pharma becomes the first natural pharma firm to adopt a Bitcoin reserve strategy, blending beauty with Bitcoin.”‽web:0,1,4,5post:0,1,3,5,7
However, the German government’s own history with Bitcoin adds an ironic twist. In 2024, Germany sold off 50,000 BTC, missing out on an estimated $1.6 billion in gains due to poor timing, according to Benzinga. Evertz Pharma’s proactive approach contrasts sharply with this, positioning the company as a pioneer in a country where institutional crypto adoption has lagged behind the U.S. and Asia.‽web:16,17
Implications for Evertz Pharma and the Crypto Market
Evertz Pharma’s Bitcoin reserve strategy has far-reaching implications:
- Corporate Treasury Innovation: By adopting Bitcoin, Evertz Pharma sets a blueprint for other German and European companies to integrate digital assets into their balance sheets. This could inspire mid-sized firms, particularly in innovative sectors like biotech and cosmetics, to follow suit.‽web:1,2,5
- Strengthening Financial Resilience: Bitcoin’s role as a store of value enhances Evertz Pharma’s ability to weather economic uncertainties, such as inflation or currency fluctuations, ensuring long-term stability for its operations.‽web:0,1,2,4
- Boosting Germany’s Crypto Profile: Germany has been cautious about cryptocurrencies, with regulatory debates ongoing in the Bundestag. Evertz Pharma’s move could pressure policymakers to clarify regulations, fostering a more crypto-friendly environment.‽web:13,22
- Market Signal: The acquisition reinforces Bitcoin’s growing acceptance as a corporate asset, potentially driving further institutional demand. With Bitcoin’s price eyeing $112,500, as noted by TronWeekly, corporate purchases like Evertz Pharma’s could amplify bullish sentiment.‽web:1post:3,5
Challenges and Risks
While Evertz Pharma’s strategy is forward-thinking, it is not without risks:
- Market Volatility: Bitcoin’s price is notoriously volatile. A significant correction could impact the value of Evertz Pharma’s treasury, though the company’s long-term outlook mitigates short-term risks.‽web:1
- Regulatory Uncertainty: Germany’s regulatory framework for cryptocurrencies remains evolving. Potential restrictions on corporate crypto holdings could pose challenges, though the EU’s MiCA regulation provides some clarity.‽web:13
- Public Perception: As a cosmetics and pharma company, Evertz Pharma must balance its innovative financial strategy with maintaining consumer trust in its core business. Negative crypto sentiment could affect its brand image.
The Road Ahead
Evertz Pharma’s acquisition of 100 BTC is just the beginning. The company plans to continue deploying excess liquidity and exploring financial instruments to expand its Bitcoin holdings sustainably. This aligns with its broader vision of combining scientific innovation with financial resilience. As Dominik Evertz stated, “Bitcoin is not just an investment for us but a strategic asset that perfectly complements our vision of stability and future resilience.”‽web:0,2,4
For the broader crypto market, Evertz Pharma’s move signals a maturing landscape where private companies, not just public giants, are embracing digital assets. Posts on X reflect this sentiment, with one user noting, “Corporate adoption is gaining momentum globally in different shapes & forms!” As more firms follow Evertz Pharma’s lead, Bitcoin’s role as a corporate treasury asset could become mainstream, particularly in Europe.‽post:4
Conclusion
Evertz Pharma GmbH’s acquisition of 100 Bitcoins worth €10 million marks a historic moment for Germany’s corporate landscape and the global crypto market. As the first German company to adopt a strategic Bitcoin reserve, Evertz Pharma is redefining treasury management for private enterprises. By leveraging Bitcoin’s scarcity, liquidity, and inflation-hedging properties, the company is positioning itself for long-term financial stability while setting a precedent for others to follow.
For investors and crypto enthusiasts, this move underscores Bitcoin’s growing legitimacy as a corporate asset. As Evertz Pharma continues to build its BTC reserves, the world will be watching to see how this bold strategy shapes its future and inspires other companies in Germany and beyond. In a world where financial innovation is key, Evertz Pharma is proving that beauty and Bitcoin can indeed go hand in hand.
Disclaimer: Cryptocurrency investments are highly volatile and carry significant risks. This blog post is for informational purposes only and does not constitute financial or investment advice. Always conduct your own research before making investment decisions.
Sources:
- Bitcoin Magazine, TronWeekly, EIN Presswire, BitcoinEthereumNews, Coindoo, Newsbit, FinanzNachrichten, NorthData ‽web:0,1,2,4,5,7,9,10,15
- Posts on X ‽post:0,1,3,4,5,7
